Summary

Treatment with an angiotensin-II receptor blocker may slow the development of retinopathy among patients with type 1 diabetes, according to findings from the Diabetic Retinopathy Candesartan Trials [DIRECT] Study Programme. Although the primary endpoint was not met, secondary findings suggest that inhibition of the renin-angiotensin system may lessen the risk of microvascular complications in this patient population.